Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,441 across all filing types
Latest filing 2023-10-02 Capital/Financing Update
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Cleansing Notice 2 pages 212.7KB
Capital/Financing Update Classification · 95% confidence The document is an ASX release dated 3 October 2023, titled 'Section 708A(5)(e) disclosure notice – issue of Placement Shares'. It details the issuance of approximately 5,446,428 fully paid ordinary shares to directors following shareholder approval at a recent Extraordinary General Meeting. The document references compliance with sections of the Corporations Act related to disclosure exemptions for the share issue. There are no financial statements, earnings data, or management discussion of results. The content focuses on the issuance of new shares and related regulatory disclosure. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is under 5,000 characters and is a direct announcement of a share placement, not a report publication or certification. Therefore, the correct classification is CAP with high confidence.
2023-10-02 English
Annual Report to shareholders 103 pages 4.3MB
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2023' for Imugene Limited and covers the fiscal year ended 30 June 2023. It includes detailed sections such as Chairman's Letter, Review of Operations & Activities, Director's Report, Corporate Governance Statement, Financial Statements, and Independent Auditor's Report. The content includes comprehensive financial data, operational reviews, clinical trial updates, corporate governance, and auditor's report, all typical components of a full annual report. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement or summary. Therefore, this document fits the definition of an Annual Report (10-K).
2023-09-28 English
Preliminary Final Report - Reporting Adjustments 3 pages 164.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement titled 'Preliminary Final Report - Reporting Adjustments' dated 29 September 2023. It discusses an adjustment to the Annual Report related to the Research and Development tax incentive receivable for the year ended 30 June 2023. The document references the Annual Report and the Preliminary Final Report (Appendix 4E) but does not contain the full financial statements or comprehensive financial data itself. The length is 3810 characters, which is relatively short and the document mainly serves to notify about an adjustment to a previously released report. It is not the full Annual Report or the Preliminary Final Report itself but an announcement about an adjustment to those reports. According to the 'Menu vs Meal' rule, such a document is best classified as a Regulatory Filing (RNS) because it is an announcement related to financial reporting adjustments rather than the report itself.
2023-09-28 English
Corporate Governance Statement 2023 15 pages 1.0MB
Governance Information Classification · 95% confidence The document is titled 'Corporate Governance Statement 2023' and is prepared in accordance with ASX Listing Rule 4.10.3 for the financial year ended 30 June 2023. It discusses the company's governance framework, board structure, ethics, audit committee roles, and compliance with corporate governance principles. It references the Annual Report and other governance documents but does not contain financial statements or detailed financial performance data itself. The content focuses on governance practices, board responsibilities, and policies rather than financial results or audit opinions. Therefore, this document fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2023-09-28 English
Appendix 4G 12 pages 212.9KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a detailed key to corporate governance disclosures, indicating compliance with ASX Corporate Governance Council recommendations for the financial year ended 30 June 2023. The document includes references to the corporate governance statement being available on the company's website and clarifies that Appendix 4G is lodged with the annual report but is not a substitute for the corporate governance statement itself. The content is focused on governance disclosures rather than financial results or management changes. It is a regulatory filing required by the ASX to confirm governance disclosures and compliance, not the annual report itself or a management report. The document length is substantial (15,000 characters), and it contains detailed governance compliance information, which aligns with the purpose of Appendix 4G filings under ASX rules. Therefore, the document is best classified as a Regulatory Filing (RNS) because it is a compliance disclosure related to governance, not the full annual report or a governance report per se.
2023-09-28 English
Imugene ESG Report 2023 11 pages 1.5MB
Environmental & Social Information Classification · 95% confidence The document is titled 'ESG REPORT 2023' and focuses extensively on Environmental, Social, and Governance (ESG) metrics and disclosures. It references the company's commitment to ESG principles, governance structure, anti-corruption policies, risk management, and detailed ESG performance data for the financial year ended 30 June 2023. The content is thematic around ESG factors rather than financial results or corporate governance rules alone. It also explicitly states that it complements the Annual Report and Corporate Governance Statement but is a standalone ESG report. The length of the document (over 14,000 characters) and the detailed ESG data confirm it is a full report rather than a brief announcement or summary. Therefore, the document fits the category of Environmental & Social Information (ESG) report.
2023-09-28 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.